Is Bausch Health Companies (BHC) Among Billionaire Paul Singer's Top Long-Term Stock Picks?
Bausch & Lomb Edges Higher After Confirming Sales Process
Bausch Health Says Board Authorized Management To Explore Potential Sale Of Subsidiary Bausch + Lomb; Says Process Is Ongoing. No Decision Has Been Reached
Bausch + Lomb Brief: Adds "That Process Is Ongoing, and There Can Be No Assurance That It Will Result in a Transaction"
Bausch + Lomb Brief: Says a Potential Sale Is One of Several Options Being Explored to Complete a Full Separation From Bausch Health
Bausch + Lomb Brief: Comes After Financial Times Reported That Blackstone May Drop Out of Consortium Bidding on It
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
Bausch + Lomb Shares Down on Report That Potential Buyer May Back Out
Toronto Stocks Rise, BOC Cuts Rate by 50 Basis Points; Bausch Health Shares Down as Potential Buyer Balks
Bausch+Lomb Down 10% in US Premarket After Acquiring Elios Vision for Undisclosed Sum
Bausch + Lomb Brief: Acquiring Elios Vision, "Significantly Enhances" Glaucoma Treatment Capabilities
Why Is Bausch Health Companies Inc. (BHC) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?
Indonesia Medical Aesthetics Market Focused Insights 2024-2029, Featuring Key Vendor Profiles for AbbVie, Bausch Health, Candela, Cutera, Cynosure, Galderma, Lumenis, Merz Pharma and Sientra - ResearchAndMarkets.com
Bausch Health Companies Inc. (NYSE:BHC) Is Largely Controlled by Institutional Shareholders Who Own 56% of the Company
Bausch Health and Salix in Collaboration With Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health Taps Jonathan Sadeh as Chief Medical Officer
Bausch Health Appoints Jonathan Sadeh as Executive Vice President, Chief Medical Officer and Head of R&D >BHC
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
PrCABTREOTM (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations From Canada's Drug Agency and Quebec's INESSS
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis